The ASSAIL-MI trial: a Norwegian multicentre, randomised controlled trial designed to assess the effect of tocilizumab on ischaemia reperfusion injury in ST-elevation myocardial infarction
26 May 2018 (08:30 - 18:00)
Organised by:
Abstract
About the speaker
Oslo University Hospital Rikshospitalet, Oslo (Norway)
9 More presentations in this session
Access the full session
The Event
Heart Failure 2018
26 May 2018
08:30 CET
